Citations

Clear

14 citation(s) found for "Simadibrata, Daniel M".

Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials
Simadibrata, Daniel Martin , Lesmana, Elvira , Fass, Ronnie

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 14, 2024 | Volume: 39 | Issue: 6 | Pages: 988-999

10.1111/jgh.16486 | PMID 38353152 Get It

AbstractBackground and AimHealing rates of severe erosive esophagitis (EE; Los Angeles [LA] Grade C/D) in patients treated with a proton pump inhibitor (PPI) is suboptimal (~60–70%). Vonoprazan, a potassium‐competitive acid blocker, is suggested to have better healing rates in patients with severe EE. This meta‐analysis compares the efficacy and safety of vonoprazan 20 mg versus lansoprazole 30 mg daily in healing EE, specifically in those with LA Grade C/D.MethodsWe searched MEDLINE, Embase, and CENTRAL on May 24, 2023. Studies that randomized EE patients to vonoprazan 20 mg daily or lansoprazole 30 mg daily and compared healing rates were included. The risk of bias was assessed using Cochrane's Risk of Bias 2 tool. The fixed‐effect model was used to obtain the pooled efficacy and safety outcomes. Subgroup analysis was done to compare healing rates in mild (LA Grade A/B) versus severe EE and based on study location.ResultsFour randomized controlled trials (RCTs) with low risks of bias comprising 2208 participants were included. Vonoprazan 20 mg was superior to lansoprazole 30 mg daily in healing severe EE at all weeks (Week 2 RR 1.294 [95% CI 1.169–1.433], Week 4 1.160 [1.059–1.270], and Week 8 1.175 [95% CI 1.107–1.247]), but was similar for mild EE at all weeks (P‐interaction < 0.01). Vonoprazan 20 mg was more efficacious than lansoprazole 30 mg at Week 8 in Western versus Asian studies (P‐interaction < 0.01). Any, serious, and drug‐related treatment‐emergent adverse events were comparable between groups.ConclusionVonoprazan 20 mg is superior to lansoprazole 30 mg for healing severe EE but not mild EE. Vonoprazan 20 mg daily has a similar safety profile to lansoprazole 30 mg daily.
A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease
Simadibrata, Daniel Martin , Lesmana, Elvira , Fass, Ronnie

Mayo Clinic

Journal of Gastroenterology and Hepatology | January 24, 2024 | Volume: 39 | Issue: 5 | Pages: 796-805

10.1111/jgh.16475 | PMID 38263507 Get It

AbstractBackground and AimUp to 40% of gastroesophageal reflux disease (GERD) patients experience inadequate symptom relief with a proton pump inhibitor (PPI), termed PPI‐resistant or refractory GERD. Vonoprazan, a potassium‐competitive acid blocker, has better efficacy than PPI in suppressing gastric acid secretion. This meta‐analysis summarizes the efficacy and safety of vonoprazan for treating PPI‐resistant GERD (both erosive esophagitis [EE] and non‐erosive reflux disease [NERD]).MethodsFour electronic databases (Medline, Embase, SCOPUS, and CENTRAL) were searched for studies indexed until August 1, 2023. Both observational studies and clinical trials assessing the efficacy and safety of vonoprazan in PPI‐resistant GERD were included. Efficacy outcomes included healing and maintenance rates of EE and improvement of the Frequency Scale for Symptoms of GERD (FSSG) scores. Serious adverse events (SAEs) were considered a safety outcome. The modified Newcastle‐Ottawa Scale (NOS) was used to assess study quality.ResultsTwelve studies were included in this meta‐analysis. Healing rates of PPI‐resistant EE with vonoprazan 20 mg were 91.7% (95% CI 86.8–94.8%) and 88.5% (95% CI 69.7–96.2%) at weeks 4 and 8, respectively. For healed PPI‐resistant EE, the overall maintenance rates with vonoprazan 10 mg were 82.6% (95% 61.2–95.0%) at week 8, 86.0% (95% CI 72.1–94.7%) at week 24, and 93.8% (95% CI 69.8–99.8%) at week 48. FSSG scores were improved in 74.6% (95% CI 65.8–81.7%) and 51.9% (95% CI 37.8–65.7%) of patients at weeks 4 and 8. Overall, no SAE was reported.ConclusionVonoprazan demonstrated high efficacy in the healing and maintenance of PPI‐resistant EE and moderate efficacy for the improvement of FSSG score. Vonoprazan was well tolerated in PPI‐resistant GERD patients.
S806 Safety and Efficacy of Continuous vs Intermittent Terlipressin for Acute Esophageal Variceal Bleeding - A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nivedita, Fnu, Loganathan, Priyadarshini , Moond, Vishali , Kassab, Lena L., Patel, Parth , Simadibrata, Daniel Martin , Mohan, Babu P.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S593-S594

10.14309/01.ajg.0000952864.11206.9b Get It

ViSHWaS: Violence Study of Healthcare Workers and Systems—a global survey
Banga, Akshat , Alamoudi, Razan, Faisal, Umme Habiba , Bhatt, Gaurang , Amal, Tanya , Mendiratta, Ayushi, Bollu, Bhaswanth, Kutikuppala, L. V. Simhachalam , Lee, Joanna , Huespe, Iván , Khalid, Aisha , Rais, Mohammed Amir , Adhikari, Ramesh , Lakhani, Alisha, Garg, Piyush , Pattnaik, Harsha , Gandhi, Raghu, Ahmad, Faizan , Camacho-Leon, Génesis , N., Priya Darshini, Barrios, Nimsi Marishein, Meza, Kelly , Okonkwo, Susan , Dhabuliwo, Amuza, Hamza, Hafeez , Nemat, Arash , Essar, Mohammad Yasir , Kampa, Anne, Qasba, Rakhtan K. , Sharma, Pranjal , Dutt, Taru , Vekaria, Pratikkumar , Vukoja, Marija , Bansal, Vikas , Kutikuppala, L V Simhachalam , Bansal, Vikas , Huespe, Ivan Alfredo , Qasba, Rakhtan K , Mautong, Hans , Simadibrata, Daniel Martin , Pandit, Ramesh , Ahmad, Faizan, Ciza, Pierre N, Bansal, Vikas, Nawaz, Faisal A. , Surani, Salim , Kashyap, Rahul

Mayo Clinic

BMJ Global Health | September 11, 2023 | Volume: 8 | Issue: 9 | Pages: e013101

10.1136/bmjgh-2023-013101 | PMID 37696546 Get It

Objective To provide insights into the nature, risk factors, impact and existing measures for reporting and preventing violence in the healthcare system. The under-reporting of violence against healthcare workers (HCWs) globally highlights the need for increased public awareness and education. Methods The Violence Study of Healthcare Workers and Systems study used a survey questionnaire created using Research Electronic Data Capture (REDCap) forms and distributed from 6 June to 9 August 2022. Logistic regression analysis evaluated violence predictors, including gender, age, years of experience, institution type, respondent profession and night shift frequency. A χ 2 test was performed to determine the association between gender and different violence forms. Results A total of 5405 responses from 79 countries were analysed. India, the USA and Venezuela were the top three contributors. Female respondents comprised 53%. The majority (45%) fell within the 26–35 age group. Medical students (21%), consultants (20%), residents/fellows (15%) and nurses (10%) constituted highest responders. Nearly 55% HCWs reported firsthand violence experience, and 16% reported violence against their colleagues. Perpetrators were identified as patients or family members in over 50% of cases, while supervisor-incited violence accounted for 16%. Around 80% stated that violence incidence either remained constant or increased during the COVID-19 pandemic. Among HCWs who experienced violence, 55% felt less motivated or more dissatisfied with their jobs afterward, and 25% expressed willingness to quit. Univariate analysis revealed that HCWs aged 26–65 years, nurses, physicians, ancillary staff, those working in public settings, with >1 year of experience, and frequent night shift workers were at significantly higher risk of experiencing violence. These results remained significant in multivariate analysis, except for the 55–65 age group, which lost statistical significance. Conclusion This global cross-sectional study highlights that a majority of HCWs have experienced violence, and the incidence either increased or remained the same during the COVID-19 pandemic. This has resulted in decreased job satisfaction.